Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | PHC1 | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | ANKRD13B | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | DHX30 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
mRNA | FAM120B | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
mRNA | E2F2 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
mRNA | RCC2 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
mRNA | CHMP4B | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
mRNA | CHD4 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
mRNA | POLE | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | ARHGEF28 | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-05 |